Headsafe
Founded 2017 · 1 employees on LinkedIn · 2 known investors
Headsafe is a brain health technology company whose product, Nurochek, is an FDA-cleared portable brain scanner that uses Visual Evoked Potentials and proprietary algorithms to deliver objective concussion assessment in about two minutes without a baseline. It serves emergency departments, sports medicine programs, neurology practices, urgent care centers, and imaging facilities.
Also known as Headsafe™ · Nurochek · NUROCHEK
Founders & leadership
Headsafe was founded in 2017 by Adrian Cohen.
Investors · 2
Company profile
researched Aug 2026Headsafe is a brain health technology company whose flagship product, Nurochek, is described by the company as the world's first FDA-cleared portable brain scanner. The device uses EEG and Visual Evoked Potential (VEP) technology with proprietary algorithms to measure brain function directly, producing an objective concussion assessment in about two minutes without requiring a pre-injury baseline. The company states each scan analyses more than 400,000 data points, that the technology draws on eight years of AI and machine-learning development and validation, and that it is protected by seven international patents. Indications for use cover ages 12-44, with exact specifications set out in the company's Indications for Use documentation.
The workflow is presented in three steps: a headset is placed on the patient and guided software runs a two-minute assessment; AI-supported analysis processes the visual evoked potentials against normative data; and clinicians receive objective results intended to support clinical judgement. The product is paired with a secure cloud platform and is positioned for use in emergency departments, on sports sidelines, in ambulances, urgent care and neurology clinics. Headsafe describes itself more broadly as a brain health technology platform, with Nurochek as the first product and further products planned.
Headsafe states its technology has been validated through multi-site studies across Australia, New Zealand and the United States, and describes it as peer-reviewed and used by universities and hospitals.
Founding story
The company was founded in 2017. Founder Dr. Adrian Cohen, a frontline physician who serves as Chief Innovation Officer, is described as having started the company after observing that concussion and brain injury decisions relied on tools that were slow, subjective and easy to influence. Investor Investible lists Adrian Cohen and Kay Trippner as founders.
Business model
Headsafe develops and commercialises a medical device and accompanying cloud software, selling to healthcare providers directly and through authorised distributors.
The company markets Nurochek to clinical settings via demo requests and a sales team; for imaging centres it positions the assessment as reimbursable and as a new revenue stream for the provider.
Traction
Headsafe reports FDA clearance for Nurochek, seven international patents, multi-site validation studies across Australia, New Zealand and the United States, use of the technology by universities and hospitals, and appointed distributors covering the United States and Australia/New Zealand.
Latest developments
In May 2024, founder Adrian Cohen began approaching investors for an approximately $5 million raise to take the NuroCHEK device offshore, targeting the United States market and aiming to be an established provider by 2026.
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
Headsafe positions Nurochek as the first FDA-cleared portable brain scanner and aims to become a global benchmark for objective, point-of-care brain health assessment, contrasting its direct measurement of brain function with subjective symptom, balance and memory testing.
Key claimed differentiators are FDA clearance, portability suitable for sidelines and ambulances, a two-minute assessment, no baseline requirement, objective data that the company says cannot be faked or misreported, and functional brain data that complements structural imaging such as CT.
Technology
Nurochek combines EEG and Visual Evoked Potential measurement with proprietary, AI-supported algorithms that analyse more than 400,000 data points per scan and compare results against normative data, removing the need for a pre-injury baseline. The company cites eight years of research and seven international patents, and pairs the portable headset with guided software and a secure cloud platform.
Go-to-market
Headsafe sells through a direct sales/demo motion on its website and through key distributors: Spartan Medical, a veteran-owned distribution and government contracting partner with VA/DoD access and federal procurement expertise, covers the United States, and MedTech Labs Group is the authorised distributor for Australia and New Zealand.
Emergency medicine departments, sports medicine programmes and athletic trainers, urgent care centres and imaging centres, plus neurology clinics and ambulance services.
Geography
Headsafe is associated with Australia through its investor base and the Australian press coverage of its raise, has validation studies across Australia, New Zealand and the United States, and distributes via partners in the United States (Spartan Medical) and Australia/New Zealand (MedTech Labs Group). US market expansion was the stated purpose of its 2024 raise.
History
Founded in 2017, Headsafe developed the Nurochek system over roughly eight years of research and validation studies conducted in Australia, New Zealand and the United States, and obtained FDA clearance for the device. Australian early-stage investor Investible partnered with the company in 2019 and again in 2021, at seed and pre-Series A stages, investing via its Early Stage Fund 1 and the Club Investible Syndicate. In May 2024 founder Adrian Cohen began raising approximately $5 million to expand into the United States, with the aim of becoming an established provider there by 2026.
Risks & controversies
Commercialisation depends on regulatory clearance limits — the device is indicated for ages 12-44 and subject to contraindications set out in its Indications for Use — and on securing additional capital for the planned US expansion.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Competitors · 2
by search overlap
Companies competing with Headsafe for the same Google search keywords, organic and paid, via search-intersection analysis.
Timeline · 5
launches, deals, and filingsHeadsafe lists Spartan Medical as its US distribution and government contracting partner with VA/DoD access, and MedTech Labs Group as authorised distributor for Australia and New Zealand.
Headsafe states Nurochek is FDA-cleared, indicated for ages 12-44, with specifications set out in its Indications for Use documentation.
Founder Adrian Cohen began contacting investors to raise about $5 million to take the NuroCHEK concussion device into the United States, aiming to be an established provider by 2026.
$5M source ↗
Investible recorded a second partnering date with Headsafe in 2021, at pre-Series A stage.
Australian early-stage investor Investible invested in Headsafe via Early Stage Fund 1 and the Club Investible Syndicate, first partnering in 2019 at seed stage.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 8
primary sources listed
- Headsafeheadsafe.com · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Headsafe do?
- Headsafe makes Nurochek, an FDA-cleared portable brain scanner giving objective concussion assessment in about two minutes.
- Who founded Headsafe?
- Headsafe was founded by Adrian Cohen in 2017.
- Who are Headsafe's investors?
- Headsafe's investors include Artesian, Pacific Channel.